You Position: Home > Paper
Influence of ligustrazini on change of plasma PAI-1 level in patients with type 2 diabetes
( views:149, downloads:0 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
- Issue:
- 8
- DOI:
- 10.3760/cma.j.issn.1008-6706.2002.08.005
- Key Word:
- 川芎嗪 2型糖尿病 纤溶酶原激活物抑制剂-1(PAI-1)
Abstract： 目的观察川芎嗪对2型糖尿病病人血浆纤溶酶原激活抑制剂-1(PAI-1)活性水平的影响.方法 60例2型糖尿病病人随机分为治疗组和对照组,分别给予川芎嗪(120 mg/d)和生理盐水静滴,20 d为1个疗程.治疗前后测定PAI-1.结果两组病人治疗后血浆PAI-1活性水平均有下降,治疗组下降显著,两组相比差异有显著意义(P＜0.01).结论川芎嗪可降低2型糖尿病病人血浆PAI-1活性水平.
- [1]Y.W. Cho,D.H. Yang,D.Y. Oh,etc.Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: Implication for diabetic retinopathy[J].1994,22(2-3).
- [2]阮秋蓉,宋建新,邓仲端.川芎嗪抗血栓形成的机制研究[J].1998,(4).
- [3]商淑华,宁光,戴蒙,等.NIDDM 中 PAI-1 与高胰岛素血症及胰岛素抵抗的关系[J].1997,(1).
- [4]S, Tomooka,W A, Border,B C, Marshall,etc.Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.[J].1992,42(6).